Sutro Biopharma Inc reports results for the quarter ended June 30 - Earnings Summary

Sutro Biopharma

12/08/2025 01:02

Sutro Biopharma Inc STRO.OQ reported a quarterly adjusted loss of 14 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -59 cents.  The mean expectation of ten analysts for the quarter was for a loss of 40 cents per share. Wall Street expected results to range from -64 cents to -4 cents per share.

Revenue rose 148% to $63.75 million from a year ago; analysts expected $14.25 million.

Sutro Biopharma Inc's reported EPS for the quarter was a loss of 14 cents​.

The company reported a quarterly loss of $11.5 million.

Sutro Biopharma Inc shares had risen by 12.4% this quarter and lost 56.4% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 19.2% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 4 "hold" and 1 "sell" or "strong sell."

Wall Street's median 12-month price target for Sutro Biopharma Inc is $2.00, about 61.4% above its last closing price of $0.77

This summary was machine generated from LSEG data August 12 at 12:01 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
-0.40
-0.14
Beat
Mar. 31 2025
-0.71
-0.91
Missed
Dec. 31 2024
-0.83
-0.89
Missed
Sep. 30 2024
-0.73
-0.59
Beat